Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
The Effects of Fasinumab on Peripheral Nerve Function and Ganglion Anatomy: Results From a Randomized, Double-Blind, Placebo-Controlled Study in Patients With Pain Due to Osteoarthritis of the Knee or Hip, and a Series of Nonclinical Studies.
Journal: Current therapeutic research, clinical and experimental
Published: May 07, 2025
Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hip.
Journal: BMC musculoskeletal disorders
Published: July 26, 2024
A phase III study to evaluate the long-term safety and efficacy of fasinumab in patients with pain due to osteoarthritis of the knee or hip.
Journal: Osteoarthritis and cartilage open
Published: July 19, 2024
Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis.
Journal: Frontiers in immunology
Published: July 17, 2024
Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19.
Journal: Journal of the Pediatric Infectious Diseases Society
Published: April 19, 2024
Prevalence of preexisting articular bone pathology in patients with osteoarthritis screened for fasinumab clinical trials identified by X-ray or magnetic resonance imaging.
Journal: Osteoarthritis and cartilage
Published: January 15, 2024
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.
Journal: JAMA network open
Published: August 15, 2022
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19.
Journal: The Journal of infectious diseases
Published: April 22, 2022
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
Journal: The Lancet. Infectious diseases
Published: April 04, 2022
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: January 19, 2022
Last Updated: 09/26/2026